Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome

PURPOSE: Teduglutide, a glucagon-like peptide-2 analog, has demonstrated efficacy in reducing parenteral support (PS) among patients with short bowel syndrome with intestinal failure (SBS–IF). This study aims to identify a subpopulation of SBS–IF patients for whom teduglutide has an especially prono...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kristina S, Xie, Jipan, Tang, Wenxi, Zhao, Jing, Jeppesen, Palle B, Signorovitch, James E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065551/
https://www.ncbi.nlm.nih.gov/pubmed/30100725
http://dx.doi.org/10.2147/TCRM.S166081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065551/
https://www.ncbi.nlm.nih.gov/pubmed/30100725
http://dx.doi.org/10.2147/TCRM.S166081

Ejemplares similares